Real-World Evidence Solutions for Oncology: How Patient Data Is Shaping Cancer Research

Cancer research is becoming increasingly data-driven as researchers, healthcare providers, and regulators look beyond traditional clinical trials to understand what happens to patients in everyday healthcare settings. Real-World Evidence (RWE) Solutions for Oncology are becoming an important part of this shift, helping transform information generated during routine cancer care into insights about treatment outcomes, safety, patient characteristics, and treatment patterns.

The growing importance of this field is reflected in its expanding use across oncology research. Grand View Research valued the Real-World Evidence Solutions for Oncology market at USD 1,437.1 million by 2033, highlighting the increasing attention being given to real-world data and evidence as cancer treatment becomes more personalized and complex.

Why Real-World Evidence Matters in Oncology

Clinical trials remain essential for evaluating the safety and effectiveness of new cancer treatments. However, trial participants are selected according to specific eligibility criteria and may not represent every patient encountered in everyday oncology practice.

Real-world evidence provides an additional perspective.

Information collected during routine healthcare can include electronic health records, insurance claims, cancer registries, laboratory results, treatment records, and patient-reported information. When appropriately analyzed, these sources can help researchers understand how therapies perform across different patient groups and healthcare settings.

The FDA recognizes real-world data as information related to patient health status and healthcare delivery that is routinely collected from sources such as electronic health records, claims data, registries, and other healthcare settings.

From Healthcare Data to Reliable Evidence

Having access to large amounts of healthcare information does not automatically produce meaningful evidence.

Cancer datasets can contain missing information, inconsistent terminology, differences in documentation, and variations between healthcare systems. Researchers therefore need appropriate methods to determine whether information is sufficiently reliable and relevant for a particular research question.

This has made data quality, validation, interoperability, and methodological consistency increasingly important areas of oncology RWE.

The FDA's Oncology Real-World Evidence Program focuses on advancing the appropriate use of real-world data and evidence in oncology product development and regulatory decision-making.

RWE Is Moving Closer to Regulatory Research

The role of real-world evidence is also expanding within regulatory science.

Regulators are increasingly exploring how real-world data can complement traditional clinical research, particularly when researchers need to study questions that may be difficult to answer through randomized trials alone.

The FDA has been investigating approaches for using real-world data to emulate randomized clinical trials. Its RCT-DUPLICATE initiative, for example, examines whether non-randomized real-world studies can reproduce randomized trial results and under what circumstances these approaches may provide reliable evidence.

For oncology, this can be particularly relevant as treatment options become more specialized and patient populations become increasingly diverse.

Understanding Cancer Treatment Beyond the Trial

One of the strongest applications of RWE is understanding what happens after a therapy enters routine clinical practice.

Researchers can examine treatment sequencing, duration of therapy, patient outcomes, safety patterns, healthcare utilization, and differences between patient populations.

This information can provide context that may not be fully captured during controlled clinical trials.

For example, a therapy may be studied in a specific group of patients during development, while its eventual use can involve people with different ages, health conditions, treatment histories, or disease characteristics.

Real-world evidence can help researchers examine these broader experiences.

Artificial Intelligence Is Expanding RWE Capabilities

Artificial intelligence and advanced analytics are also becoming increasingly relevant to oncology RWE.

Cancer records can contain enormous amounts of information, including clinical notes, pathology information, imaging results, treatment histories, and other unstructured data. Reviewing these records manually can be difficult when researchers need to analyze information from large patient populations.

AI-based technologies can help identify relevant information, organize complex datasets, and detect patterns that may otherwise be difficult to identify.

However, AI does not eliminate the need for scientific validation. The reliability of an RWE study still depends on the quality of the underlying data, the study methodology, appropriate analysis, and careful interpretation.

Real-World Data Can Reveal Treatment Patterns

Cancer treatment can involve multiple lines of therapy and changing treatment decisions over time. RWE can provide a longitudinal view of these experiences.

Researchers can investigate how therapies are used in practice, how treatment decisions vary between populations, and what outcomes are observed over longer periods.

This can be particularly valuable for understanding populations that may have limited representation in conventional clinical research.

As oncology increasingly adopts personalized and targeted treatments, understanding these differences can become even more important.

Data Quality Remains a Major Consideration

The growing availability of healthcare information also creates challenges.

Data may come from different healthcare systems and may have been collected for purposes other than research. Differences in coding, documentation, data structures, and completeness can make it difficult to combine information reliably.

Researchers therefore need to evaluate whether datasets are fit for purpose before drawing conclusions.

Privacy and security are equally important because oncology datasets can contain highly sensitive patient information. Responsible data management is essential when information from multiple sources is being connected and analyzed.

Connecting Clinical Trials With Real-World Care

RWE should not be viewed as a replacement for clinical trials.

Instead, clinical trials and real-world evidence can provide complementary perspectives. Trials offer controlled environments for evaluating treatments, while RWE can help researchers understand how those treatments perform across broader populations and everyday healthcare settings.

Together, these approaches can create a more complete picture of a therapy throughout its development and use.

New Cancer Treatments Are Creating Additional Evidence Needs

The oncology landscape is also evolving rapidly as researchers explore increasingly personalized treatment approaches. Recent progress toward human testing of Russia's AI-backed personalized mRNA cancer vaccine illustrates the pace at which new cancer therapies are being developed. Landmark in Oncology: Cancer Vaccine Trials to Begin in Russia

As innovative treatments move from development into broader clinical use, understanding how they perform across diverse patient populations will become increasingly important. This creates another area where reliable real-world evidence can complement controlled clinical research.

The Future of Real-World Evidence in Oncology

The role of real-world evidence in cancer research is moving toward a more continuous model of evidence generation. Instead of relying only on information collected during clinical development, researchers can continue learning from patients as treatments are used in everyday healthcare.

The opportunity is not simply to collect more data. It is to transform diverse healthcare information into reliable, relevant, and actionable evidence.

As oncology becomes more personalized and treatment options continue to evolve, RWE solutions can help bridge the gap between what is observed in clinical research and what happens in real-world cancer care.